Immunotherapy efficacy of strong positive PD-L1 expression non-small cell lung cancer (NSCLC) patients: A systematic review and meta-analysis.

e21701Background: Immune-checkpoint inhibitors (ICIs) based therapy has been approved as the new 1L standard of care in advanced PD-L1 strong positive (>=50%) non-small cell lung cancer (NSCLC). Ho...